Neuphoria Therapeutics (NEUP) Accumulated Expenses (2021 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Accumulated Expenses of $886124.0 for Q1 2026, up 122.84% year-over-year from $397652.0 in Q1 2025, and down 57.1% quarter-over-quarter from $2.1 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Accumulated Expenses (2021 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Accumulated Expenses for 6 consecutive years, with $886124.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 122.84% year-over-year to $886124.0; the TTM figure through Mar 2026 stood at $886124.0 (up 122.84% YoY), while the FY2025 annual figure was $3.0 million, up 101.59% from the prior year.
- Accumulated Expenses slipped to $886124.0 in Q1 2026 per NEUP's latest filing, from $2.1 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $3.7 million in Q3 2025 and bottomed at $305452.1 in Q2 2023.
- Historically, Accumulated Expenses has averaged $1.5 million across 5 years, with a median of $990981.0 in 2024.
- Annual changes were most pronounced in 2023 — Accumulated Expenses slumped 65.31% — and 2024, when it jumped 379.1%.
- Neuphoria Therapeutics' Accumulated Expenses stood at $880579.6 in 2022, then plunged by 65.31% to $305452.1 in 2023, then surged by 159.9% to $793881.0 in 2024, then jumped by 160.19% to $2.1 million in 2025, then sank by 57.1% to $886124.0 in 2026.
- Business Quant data shows NEUP's Accumulated Expenses at $886124.0 in Q1 2026, $2.1 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 886,124.00 |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | 3.67 Mn |
| Jun 30, 2025 | 2.95 Mn |
| Mar 31, 2025 | 397,652.00 |
| Dec 31, 2024 | 793,881.00 |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Jun 30, 2023 | 305,452.09 |
| Jun 30, 2022 | 880,579.56 |
| Jun 30, 2021 | 286,411.23 |